Exhibit 99.1 Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%. • Adjusted EBITDA of $54.1 million resulting in an Adjusted EBITDA margin of 8.5%. • Raises revenue outlook for full year 2024 and reiterates full year 2024 Adjusted EBITDA guidance. WASHINGTON (May 9, 2024) – Evolent ...